Search

Your search keyword '"Trpkov, Kiril"' showing total 640 results
Start Over "Trpkov, Kiril"
640 results on '"Trpkov, Kiril"'

101. Sarcomatoid Urothelial Carcinoma Arising in Autosomal Dominant Polycystic Kidney Disease: A Case Report and Literature Review.

Author

Bolous, Yousef, Trpkov, Kiril, Siadat, Farshid, El Hallani, Soufiane, Merrimen, Jennifer, and Wang, Cheng

Subjects
*POLYCYSTIC kidney disease, *TRANSITIONAL cell carcinoma, *RENAL cell carcinoma, *LITERATURE reviews, *KIDNEY pelvis
Abstract

Autosomal dominant polycystic kidney disease (ADPKD) may be associated with various epithelial malignancies. The most reported ones are papillary renal cell carcinoma (RCC) and clear cell RCC. Only one noninvasive urothelial carcinoma arising in the renal pelvis has been previously reported in the setting of ADPKD in the English literature. A 52-year-old patient with ADPKD and a history of renal transplant presented with a poorly differentiated sarcomatoid neoplasm in his native left polycystic kidney. A recognizable urothelial or renal cell carcinoma differentiation was not identified in the resected neoplasm microscopically. The initial diagnosis for this specimen was challenging on morphology and immunohistochemistry, but targeted next-generation sequencing provided molecular evidence in support of urothelial origin, indicating a hotspot mutation −124 C > T in the TERT promoter (C228 T) and loss of heterozygosity on chromosomes 9p and 8p. This tumor is unique because, to our knowledge, this is the first report of upper tract sarcomatoid urothelial carcinoma in a patient with ADPKD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

103. Changes in risk-group stratification of patients undergoing radical prostatectomy at the Southern Alberta Institute of Urology over time

Author

Shiff,Benjamin, Patel,Premal, Trpkov,Kiril, and Gotto,Geoffrey

Subjects
Research and Reports in Urology, active surveillance, prostate cancer, radical prostatectomy, Original Research
Abstract

Benjamin Shiff,1 Premal Patel,1 Kiril Trpkov,2 Geoffrey T Gotto3 1Division of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada; 2Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada; 3Division of Urology, Department of Surgery, University of Calgary, Calgary, AB, Canada Introduction: Prostate cancer is the most common cancer among men, but overall mortality rates remain low, due to the preponderance of low-risk disease. Over the last decade, there has been a shift toward more conservative management in low-risk prostate cancer, in order to minimize unnecessary intervention. This study aimed to evaluate the number of low-risk radical prostatectomies (RPs) being performed at the Southern Alberta Institute of Urology over a 10-year period. Methods: We retrospectively reviewed all patients who underwent RP from 2005 to 2014 at our institution. Patients were stratified by D’Amico risk classification and grade group based on 12-core transrectal ultrasound–guided biopsy (TRUS-bx) results. RP findings are reported from February 2005 to October 2014 to describe concordance between TRUS-bx and RPs. Basic descriptive analyses were used for this study. Results: Over the study period, 2,310 RPs were performed in our institution. Overall, 35.2% of these were performed on men with low-risk prostate cancer. From 2005 to 2014, the proportion of RPs performed for low-risk prostate cancer dropped from 54.0% to 8.9%, and 49.8% of patients who underwent RP for low-risk disease experienced pathologic upgrading, though only 3.8% were upgraded to grade group 3 or greater. Other adverse pathological findings were uniformly low among the low-risk group. Conclusion: The proportion of patients undergoing RP at our center for low-risk prostate cancer decreased significantly over the 10 years evaluated in this study, reflecting current global trends toward active surveillance in the management of low-risk prostate cancer. Keywords: radical prostatectomy, prostate cancer, active surveillance

Published
2019

104. Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists

Author

Berney, Daniel M, Algaba, Ferran, Amin, Mahul, Delahunt, Brett, Compérat, Eva, Epstein, Jonathan I, Humphrey, Peter, Idrees, Mohammed, Lopez-Beltran, Antonio, Magi-Galluzzi, Cristina, Mikuz, Gregor, Montironi, Rodolfo, Oliva, Esther, Srigley, John, Reuter, Victor E, Trpkov, Kiril, Ulbright, Thomas M, Varma, Murali, Verrill, Clare, Young, Robert H, Zhou, Ming, and Egevad, Lars

Published
2015
Full Text
View/download PDF

106. 99mTc-Sestamibi SPECT/CT and histopathological features of oncocytic renal neoplasia.

Author

Tzortzakakis, Antonios, Papathomas, Thomas, Gustafsson, Ove, Gabrielson, Stefan, Trpkov, Kiril, Ekström-Ehn, Linnea, Arvanitis, Alexandros, Holstensson, Maria, Karlsson, Mattias, Kokaraki, Georgia, and Axelsson, Rimma

Subjects
SINGLE-photon emission computed tomography, RECEIVER operating characteristic curves, COMPUTED tomography
Abstract

99mTc-Sestamibi Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) contributes to the non-invasive differentiation of renal oncocytoma (RO) from renal cell carcinoma (RCC) by characterising renal tumours as Sestamibi positive or Sestamibi negative regarding their 99mTc-Sestamibi uptake compared to the non-tumoral renal parenchyma. To determine whether 99mTc- Sestamibi uptake in renal tumour and the non-tumoral renal parenchyma measured using Standard Uptake Value (SUV) SPECT, has a beneficial role in differentiating RO from RCC. Fifty-seven renal tumours from 52 patients were evaluated. In addition to visual evaluation of 99mTc-Sestamibi uptake, SUVmax measurements were performed in the renal tumour and the ipsilateral non-tumoral renal parenchyma. Analysis of the area under the receiver operating characteristic curve identified an optimal cut-off value for detecting RO, based on the relative ratio of 99mTc- Sestamibi uptake. Semiquantitative evaluation of 99mTc-Sestamibi uptake did not improve the performance of 99mTc- Sestamibi SPECT/CT in detecting RO. 99mTc- Sestamibi SPECT/CT identifies a group of mostly indolent Sestamibi-positive tumours with low malignant potential containing RO, Low-Grade Oncocytic Tumours, Hybrid Oncocytic Tumours, and a subset of chromophobe RCCs. The imaging limitations for accurate differentiation of Sestamibi-positive renal tumours mirror the recognised diagnostic complexities of the histopathologic evaluation of oncocytic neoplasia. Patients with Sestamibi-positive renal tumours could be better suited for biopsy and follow-up, according to the current active surveillance protocols. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

109. The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer

Author

Baydar, Dilek Ertoy (ORCID 0000-0003-0784-8605 & YÖK ID 8025), Epstein, Jonathan I.; Amin, Mahul B.; Fine, Samson W.; Algaba, Ferran; Aron, Manju; Beltran, Antonio Lopez; Brimo, Fadi; Cheville, John C.; Colecchia, Maurizio; Comperat, Eva; da Cunha, Isabela Werneck; Delprado, Warick; DeMarzo, Angelo M.; Giannico, Giovanna A.; Gordetsky, Jennifer B.; Guo, Charles C.; Hansel, Donna E.; Hirsch, Michelle S.; Huang, Jiaoti; Humphrey, Peter A.; Jimenez, Rafael E.; Khani, Francesca; Kong, Qingnuan; Kryvenko, Oleksandr N.; Kunju, L. Priya; Lal, Priti; Latour, Mathieu; Lotan, Tamara; Maclean, Fiona; Magi-Galluzzi, Cristina; Mehra, Rohit; Menon, Santosh; Miyamoto, Hiroshi; Montironi, Rodolfo; Netto, George J.; Nguyen, Jane K.; Osunkoya, Adeboye O.; Parwani, Anil; Robinson, Brian D.; Rubin, Mark A.; Shah, Rajal B.; So, Jeffrey S.; Takahashi, Hiroyuki; Tavora, Fabio; Tretiakova, Maria S.; True, Lawrence; Wobker, Sara E.; Yang, Ximing J.; Zhou, Ming; Zynger, Debra L.; Trpkov, Kiril, School of Medicine, Baydar, Dilek Ertoy (ORCID 0000-0003-0784-8605 & YÖK ID 8025), Epstein, Jonathan I.; Amin, Mahul B.; Fine, Samson W.; Algaba, Ferran; Aron, Manju; Beltran, Antonio Lopez; Brimo, Fadi; Cheville, John C.; Colecchia, Maurizio; Comperat, Eva; da Cunha, Isabela Werneck; Delprado, Warick; DeMarzo, Angelo M.; Giannico, Giovanna A.; Gordetsky, Jennifer B.; Guo, Charles C.; Hansel, Donna E.; Hirsch, Michelle S.; Huang, Jiaoti; Humphrey, Peter A.; Jimenez, Rafael E.; Khani, Francesca; Kong, Qingnuan; Kryvenko, Oleksandr N.; Kunju, L. Priya; Lal, Priti; Latour, Mathieu; Lotan, Tamara; Maclean, Fiona; Magi-Galluzzi, Cristina; Mehra, Rohit; Menon, Santosh; Miyamoto, Hiroshi; Montironi, Rodolfo; Netto, George J.; Nguyen, Jane K.; Osunkoya, Adeboye O.; Parwani, Anil; Robinson, Brian D.; Rubin, Mark A.; Shah, Rajal B.; So, Jeffrey S.; Takahashi, Hiroyuki; Tavora, Fabio; Tretiakova, Maria S.; True, Lawrence; Wobker, Sara E.; Yang, Ximing J.; Zhou, Ming; Zynger, Debra L.; Trpkov, Kiril, and School of Medicine

Abstract

Context: controversies and uncertainty persist in prostate cancer grading. Objective: to update grading recommendations Data sources: critical review of the literature along with pathology and clinician surveys. Conclusions: percent Gleason pattern 4 (%GP4) is as follows: (1) report %GP4 in needle biopsy with Grade Groups (GrGp) 2 and 3, and in needle biopsy on other parts (jars) of lower grade in cases with at least 1 part showing Gleason score (GS) 4 + 4 = 8; and (2) report %GP4: less than 5% or less than 10% and 10% increments thereafter. Tertiary grade patterns are as follows: (1) replace "tertiary grade pattern'' in radical prostatectomy (RP) with "minor tertiary pattern 5 (TP5),'' and only use in RP with GrGp 2 or 3 with less than 5% Gleason pattern 5; and (2) minor TP5 is noted along with the GS, with the GrGp based on the GS. Global score and magnetic resonance imaging (MRI)targeted biopsies are as follows: (1) when multiple undesignated cores are taken from a single MRI-targeted lesion, an overall grade for that lesion is given as if all the involved cores were one long core; and (2) if providing a global score, when different scores are found in the standard and the MRI-targeted biopsy, give a single global score (factoring both the systematic standard and the MRI-targeted positive cores). Grade Groups are as follows: (1) Grade Groups (GrGp) is the terminology adopted by major world organizations; and (2) retain GS 3 + 5 = 8 in GrGp 4. Cribriform carcinoma is as follows: (1) report the presence or absence of cribriform glands in biopsy and RP with Gleason pattern 4 carcinoma. Intraductal carcinoma (IDCP) is as follows: (1) report IDC-P in biopsy and RP; (2) use criteria based on dense cribriform glands (>50% of the gland is composed of epithelium relative to luminal spaces) and/or solid nests and/or marked pleomorphism/necrosis; (3) it is not necessary to perform basal cell immunostains on biopsy and RP to identify IDC-P if the results would not change the, NA

Published
2021

111. Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists

Author

Seipel, Amanda H, Delahunt, Brett, Samaratunga, Hemamali, Amin, Mahul, Barton, Joel, Berney, Daniel M, Billis, Athanase, Cheng, Liang, Comperat, Eva, Evans, Andrew, Fine, Samson W, Grignon, David, Humphrey, Peter A, Magi-Galluzzi, Cristina, Montironi, Rodolfo, Sesterhenn, Isabell, Srigley, John R, Trpkov, Kiril, van der Kwast, Theo, Varma, Murali, Zhou, Ming, Ahmad, Amar, Moss, Sue, and Egevad, Lars

Published
2014
Full Text
View/download PDF

113. The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia

Author

Amin, Mahul B., primary, Comperat, Eva, additional, Epstein, Jonathan I., additional, True, Lawrence D., additional, Hansel, Donna, additional, Paner, Gladell P., additional, Al-Ahmadie, Hikmat, additional, Baydar, Dilek, additional, Bivalacqua, Trinity, additional, Brimo, Fadi, additional, Cheng, Liang, additional, Cheville, John, additional, Dalbagni, Guido, additional, Falzarano, Sara, additional, Gordetsky, Jennifer, additional, Guo, Charles C., additional, Gupta, Sounak, additional, Hes, Ondra, additional, Iyer, Gopa, additional, Kaushal, Seema, additional, Kunju, Lakshmi, additional, Magi-Galluzzi, Cristina, additional, Matoso, Andres, additional, Netto, George, additional, Osunkoya, Adeboye O., additional, Pan, Chin Chen, additional, Pivovarcikova, Kristina, additional, Raspollini, Maria R., additional, Reis, Henning, additional, Rosenberg, Jonathan, additional, Roupret, Morgan, additional, Shah, Rajal B., additional, Shariat, Shahrokh, additional, Trpkov, Kiril, additional, Weyerer, Veronika, additional, Zhou, Ming, additional, McKenney, Jesse, additional, and Reuter, Victor E., additional

Published
2021
Full Text
View/download PDF

114. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers

Author

Compérat, Eva, primary, Amin, Mahul B., additional, Epstein, Jonathan I., additional, Hansel, Donna E., additional, Paner, Gladell, additional, Al-Ahmadie, Hikmat, additional, True, Larry, additional, Bayder, Dilek, additional, Bivalacqua, Trinity, additional, Brimo, Fadi, additional, Cheng, Liang, additional, Cheville, John, additional, Dalbagni, Guido, additional, Falzarano, Sara, additional, Gordetsky, Jennifer, additional, Guo, Charles, additional, Gupta, Sounak, additional, Hes, Ondrej, additional, Iyer, Gopa, additional, Kaushal, Seema, additional, Kunju, Lakshmi, additional, Magi-Galluzzi, Cristina, additional, Matoso, Andres, additional, McKenney, Jesse, additional, Netto, George J., additional, Osunkoya, Adeboye O., additional, Pan, Chin Chen, additional, Pivovarcikova, Kristina, additional, Raspollini, Maria R., additional, Reis, Henning, additional, Rosenberg, Jonathan, additional, Roupret, Morgan, additional, Shah, Rajal B., additional, Shariat, Shahrokh F., additional, Trpkov, Kiril, additional, Weyerer, Veronika, additional, Zhou, Ming, additional, and Reuter, Victor, additional

Published
2021
Full Text
View/download PDF

115. Differentiation of Renal Oncocytoma From Renal Cell Carcinoma Using 99mTc-Sestamibi SPECT/CT.

Author

Tzortzakakis, Antonios, primary, Papathomas, Thomas, additional, Gustafsson, Ove, additional, Gabrielson, Stefan, additional, Trpkov, Kiril, additional, Ekström-Ehn, Linnea, additional, Bozoky, Bela, additional, Wang, Wanzhong, additional, Arvanitis, Alexandros, additional, Holstensson, Maria, additional, Karlsson, Mattias, additional, Kokaraki, Georgia, additional, Hagel, Eva, additional, and Axelsson, Rimma, additional

Published
2021
Full Text
View/download PDF

116. The characterization of [[alpha].sub.5]-integrin expression on tubular epithelium during renal injury

Author

White, Lindsay R., Blanchette, Jason B., Ren, Li, Awn, Ali, Trpkov, Kiril, and Muruve, Daniel A.

Subjects
Chronic kidney failure -- Causes of, Chronic kidney failure -- Research, Epithelial cells -- Health aspects, Epithelial cells -- Research, Biological sciences
Abstract

The hallmark of progressive chronic kidney disease is the deposition of extracellular matrix proteins and tubulointerstitial fibrosis. Integrins mediate cell-extracellular matrix interaction and may play a role tubular epithelial injury. Murine primary tubular epithelial cells (TECs) express [[alpha].sub.5]-integrin, a fibroblast marker and the natural receptor for fibronectin. Microscopy localized [[alpha].sub.5]-integrin on E-cadherin-positive cells, confirming epithelial expression. The expression of [[alpha].sub.5]-integrin increased in TECs grown on fibronectin and occurred in parallel with an upregulation of [[alpha].sub.5]-smooth muscle actin ([alpha]SMA), a marker of epithelial-mesenchymal transition (EMT). Exposure of TECs to transforming growth factor (TGF)-[beta] also increased TEC [[alpha].sub.5]-integrin expression in association with [alpha]SMA and EMT. Knock-down of [[alpha].sub.5]-integrin expression with short interfering RNA attenuated the TGF-[beta] induction of [alpha]SMA but did not alter morphologic EMT. Rather, [[alpha].sub.5]-integrin was necessary for epithelial cell migration on fibronectin but not type IV collagen during cell spreading and epithelial wound healing in vitro. Immunohistochemistry revealed basolateral tubular epithelial [[alpha].sub.5]-integrin expression in mouse kidneys after unilateral ureteric obstruction but not in contralateral control kidneys. In patient biopsies of nondiabetic kidney disease, [[alpha].sub.5]-integrin expression was increased significantly in the renal interstitium. Focal basolateral staining was also detected in injured, but not in normal, tubular epithelium. In summary, these data show that TECs are induced to express [[alpha].sub.5]-integrin during EMT and tubular epithelial injury in vitro and in vivo. These results increase our understanding of the biology of integrins during EMT and tubular injury in chronic kidney disease. chronic kidney disease; epithelial mesenchymal transition

Published
2007

117. In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on Tc-99(m)-sestamibi Single Photon Emission Computed Tomography/Computed Tomography Examination

Author

Papathomas, Thomas, Tzortzakakis, Antonios, Sun, Na, Erlmeier, Franziska, Feuchtinger, Annette, Trpkov, Kiril, Bazarova, Alina, Arvanitis, Alexandros, Wang, Wanzhong, Bozoky, Bela, Kokaraki, Georgia, Axelsson, Rimma, Walch, Axel, Papathomas, Thomas, Tzortzakakis, Antonios, Sun, Na, Erlmeier, Franziska, Feuchtinger, Annette, Trpkov, Kiril, Bazarova, Alina, Arvanitis, Alexandros, Wang, Wanzhong, Bozoky, Bela, Kokaraki, Georgia, Axelsson, Rimma, and Walch, Axel

Abstract

Background: Definite noninvasive characterisation of renal tumours positive on Tc-99m-sestamibi single photon emission computed tomography/computed tomography (SPECT/CT) examination including renal oncocytomas (ROs), hybrid oncocytic chromophobe tumours (HOCTs), and chromophobe renal cell carcinoma (chRCC) is currently not feasible. Objective: To investigate whether combined Tc-99m-sestamibi SPECT/CT and in situ metabolomic profiling can accurately characterise renal tumours exhibiting Tc-99m-sestamibi uptake. Design, setting, and participants: A tissue microarray analysis of 33 tumour samples from 28 patients was used to investigate whether their in situ metabolomic status correlates with their features on Tc-99m-sestamibi SPECT/CT examination. In order to validate emerging data, an independent cohort comprising 117 tumours was subjected to matrix-assisted laser desorption/ionisation mass spectrometry imaging (MALDI MSI). Outcome measurements and statistical analysis: MALDI MSI data analysis and image generation were facilitated by FlexImaging v. 4.2, while k-means analysis by SCiLS Lab software followed by R-package CARRoT analysis was used for assessing the highest predictive power in the differential of RO versus chRCC. Heatmap-based clustering, sparse partial least-squares discriminant analysis, and volcano plots were created with MetaboAnalyst 3.0. Results and limitations: We identified a discriminatory metabolomic signature for Tc-99m-sestamibi SPECT/CT-positive Birt-Hogg-Dube-associated HOCTs versus other renal oncocytic tumours. Metabolomic differences were also evident between Tc-99m-sestamibi-positive and Tc-99m-sestamibi-negative chRCCs, prompting additional expert review; two of three Tc-99m-sestamibi-positive chRCCs were reclassified as low-grade oncocytic tumours (LOTs). Differences were identified between distal-derived tumours from those of proximal tubule origin, including differences between ROs and chRCCs. Conclusions: The current study expands t

Published
2020

123. Gene fusion characterisation of rare aggressive prostate cancer variants—adenosquamous carcinoma, pleomorphic giant‐cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases

Author

Alhamar, Mohamed, primary, Tudor Vladislav, I, additional, Smith, Steven C, additional, Gao, Yuan, additional, Cheng, Liang, additional, Favazza, Laura A, additional, Alani, Ali M, additional, Ittmann, Michael M, additional, Riddle, Nicole D, additional, Whiteley, Lisa J, additional, Gupta, Nilesh S, additional, Carskadon, Shannon, additional, Gomez‐Gelvez, Juan C, additional, Chitale, Dhananjay A, additional, Palanisamy, Nallasivam, additional, Hes, Ondrej, additional, Trpkov, Kiril, additional, and Williamson, Sean R, additional

Published
2020
Full Text
View/download PDF

126. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer

Author

Epstein, Jonathan I., primary, Amin, Mahul B., additional, Fine, Samson W., additional, Algaba, Ferran, additional, Aron, Manju, additional, Baydar, Dilek E., additional, Beltran, Antonio Lopez, additional, Brimo, Fadi, additional, Cheville, John C., additional, Colecchia, Maurizio, additional, Comperat, Eva, additional, da Cunha, Isabela Werneck, additional, Delprado, Warick, additional, DeMarzo, Angelo M., additional, Giannico, Giovanna A., additional, Gordetsky, Jennifer B., additional, Guo, Charles C., additional, Hansel, Donna E., additional, Hirsch, Michelle S., additional, Huang, Jiaoti, additional, Humphrey, Peter A., additional, Jimenez, Rafael E., additional, Khani, Francesca, additional, Kong, Qingnuan, additional, Kryvenko, Oleksandr N., additional, Kunju, L. Priya, additional, Lal, Priti, additional, Latour, Mathieu, additional, Lotan, Tamara, additional, Maclean, Fiona, additional, Magi-Galluzzi, Cristina, additional, Mehra, Rohit, additional, Menon, Santosh, additional, Miyamoto, Hiroshi, additional, Montironi, Rodolfo, additional, Netto, George J., additional, Nguyen, Jane K., additional, Osunkoya, Adeboye O., additional, Parwani, Anil, additional, Robinson, Brian D., additional, Rubin, Mark A., additional, Shah, Rajal B., additional, So, Jeffrey S., additional, Takahashi, Hiroyuki, additional, Tavora, Fabio, additional, Tretiakova, Maria S., additional, True, Lawrence, additional, Wobker, Sara E., additional, Yang, Ximing J., additional, Zhou, Ming, additional, Zynger, Debra L., additional, and Trpkov, Kiril, additional

Published
2020
Full Text
View/download PDF

127. Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study

Author

Pires-Luis, Ana S., primary, Martinek, Petr, additional, Alaghehbandan, Reza, additional, Trpkov, Kiril, additional, Comperat, Eva M., additional, Perez Montiel, Delia M., additional, Bulimbasic, Stela, additional, Lobo, João, additional, Henrique, Rui, additional, Vanecek, Tomas, additional, Pivovarcikova, Kristyna, additional, Michalova, Kvetoslava, additional, Pitra, Tomas, additional, Hora, Milan, additional, Marques, Ana, additional, Lopes, Jose M., additional, Rogala, Joanna, additional, Mareckova, Jana, additional, Michal, Michal, additional, and Hes, Ondrej, additional

Published
2020
Full Text
View/download PDF

137. Recurrent KRASmutations are early events in the development of papillary renal neoplasm with reverse polarity

Author

Al-Obaidy, Khaleel I., Saleeb, Rola M., Trpkov, Kiril, Williamson, Sean R., Sangoi, Ankur R., Nassiri, Mehdi, Hes, Ondrej, Montironi, Rodolfo, Cimadamore, Alessia, Acosta, Andres M., Alruwaii, Zainab I., Alkashash, Ahmad, Hassan, Oudai, Gupta, Nilesh, Osunkoya, Adeboye O., Sen, Joyashree D., Baldrige, Lee Ann, Sakr, Wael A., Idrees, Muhammad T., Eble, John N., Grignon, David J., and Cheng, Liang

Abstract

We evaluated the clinicopathologic and molecular characteristics of mostly incidentally detected, small, papillary renal neoplasms with reverse polarity (PRNRP). The cohort comprised 50 PRNRP from 46 patients, divided into 2 groups. The clinically undetected (<5 mm) neoplasms (n= 34; 68%) had a median size of 1.1 mm (range 0.2–4.3 mm; mean 1.4 mm), and the clinically detected (≥5 mm) neoplasms (n= 16; 32%) which had a median size of 13 mm (range 9–30 mm; mean 16 mm). Neoplasms were positive for GATA3 (n = 47; 100%) and L1CAM (n= 34/38; 89%) and were negative for vimentin (n= 0/44; 0%) and, to a lesser extent, AMACR [(n= 12/46; 26%; weak = 9, weak/moderate = 3)]. KRASmutations were found in 44% (n= 15/34) of the clinically undetected PRNRP and 88% of the clinically detected PRNRP (n= 14/16). The two clinically detected PRNRP with wild-type KRASgene were markedly cystic and contained microscopic intracystic tumors. In the clinically undetected PRNRP, the detected KRASmutations rate was higher in those measuring ≥1 mm vs <1 mm [n = 14/19 (74%) vs n = 1/15 (7%)]. Overall, the KRASmutations were present in exon 2—codon 12: c.35 G > T (n= 21), c.34 G > T (n= 3), c.35 G > A (n= 2), c.34 G > C (n= 2) resulting in p.Gly12Val, p. Gly12Asp, p.Gly12Cys and p.Gly12Arg, respectively. One PRNRP had a G12A/V/D complex mutation. Twenty-six PRNRP were concurrently present with other tumors of different histologic subtypes in the ipsilateral kidney; molecular testing of 8 of the latter showed wild-type KRASgene despite the presence of KRASmutations in 5 concurrent PRNRP. On follow up, no adverse pathologic events were seen (range 1–160 months; mean 44 months). In conclusion, the presence of KRASmutations in small, clinically undetected PRNRP provides a unique finding to this entity and supports its being an early event in the development of these neoplasms.

Published
2022
Full Text
View/download PDF

138. ERG expression in prostate cancer biopsies with and without high-grade prostatic intraepithelial neoplasia: a study in Jordanian Arab patients

Author

Aldaoud,Najla, Graboski-Bauer,Ashley, Abdo,Nour, Al Bashir,Samir, Oweis,Ashraf O., Ebwaini,Hanadi, Hasen,Yousef, Alazab,Rami, and Trpkov,Kiril

Subjects
Research and Reports in Urology
Abstract

Najla Aldaoud,1,2 Ashley Graboski-Bauer,3 Nour Abdo,4 Samir Al Bashir,1,2 Ashraf O Oweis,5 Hanadi Ebwaini,1 Yousef Hasen,1–2,6 Rami Alazab,7 Kiril Trpkov81Department of Pathology and Microbiology, King Abdullah University Hospital, Irbid, Jordan; 2Jordan University of Science and Technology, Irbid, Jordan; 3Department of Teacher Education, University of Texas, El Paso, TX, USA; 4Department of Public Health, Jordan University of Science and Technology, Irbid, Jordan; 5Division of Nephrology, Department of Medicine, Jordan University of Science and Technology, Irbid, Jordan; 6Attasami Diagnostic Center, Tripoli, Libya; 7Division of Urology, Jordan University of Science and Technology, Irbid, Irbid; 8Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, CanadaBackground: High-grade prostatic intraepithelial neoplasia (HGPIN) is the most likely precancerous lesion for prostatic adenocarcinoma (PCa). Recent molecular studies have shown that HGPIN can harbor TMPRSS2-ERG fusion, a genetic marker also associated with PCa, which may provide an additional risk stratification tool for HGPIN, especially when present as an isolated lesion. Our aim was to assess the frequency of HGPIN and ERG expression in a cohort of prostatic needle core biopsies from Jordanian-Arab patients with PCa.Materialsand methods: We studied 109 needle core biopsies from patients with PCa. Clinical data, including age and preoperative prostate specific antigen (PSA) level, were obtained from patients’ medical records.Results: HGPIN was present in 31 (28.4 %) of the 109 cases. Of the HGPIN cases, 13 (41.9%) expressed ERG immunostain. ERG expression in HGPIN was independent of patient age at presentation (P=0.4), pre-operative PSA (P=0.9), and the grade, using the novel Grade Groups (P=0.5).Conclusion: The frequency of HGPIN in our cohort appears similar to the one found in the Western patient populations and demonstrates a comparable frequency of ERG expression in these lesions.Keywords: high-grade prostatic intraepithelial neoplasia, prostate carcinoma, ERG, immunohistochemistry

Published
2019

139. The effect of time from biopsy to radical prostatectomy on adverse pathologic outcomes

Author

Patel,Premal, Sun,Ryan, Shiff,Benjamin, Trpkov,Kiril, and Gotto,Geoffrey

Subjects
Research and Reports in Urology
Abstract

Premal Patel,1 Ryan Sun,1 Benjamin Shiff,1 Kiril Trpkov,2 Geoffrey Thomas Gotto3 1Section of Urology, University of Manitoba, Winnipeg, MB, Canada; 2Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada; 3Department of Surgery, University of Calgary, Calgary, AB, Canada Objective: To assess the impact of time between prostate cancer diagnosis on biopsy and definitive intervention with radical prostatectomy (RP) in regard to adverse pathologic outcomes using a large multi-surgeon database.Materials and methods: We retrospectively reviewed 2,728 patients who underwent RP between 2005 and 2014. Patients were stratified according to biopsy Grade Group (GG). Pathologic outcomes were evaluated for patients with Results: In total 2,310 patients met the inclusion criteria. Median time from biopsy to surgery was 83 days (range: 61–109 days). No difference was observed for patients in any risk category regarding the adverse pathologic outcomes, including GG upgrade from biopsy to prostatectomy, presence of EPE, SVI, positive surgical margins, and positive lymph node involvement, with delays of up to 6 months between biopsy and RP. Surgical margins were positive in 25% of cases with pT2 disease and 50.2% of cases with pT3 and greater disease. EPE and SVI were present in 24.5% and 7.5% of specimens, respectively.Conclusion: Surgical delays of up to 6 months following prostate biopsy were not associated with an increased risk of GG upgrading, EPE, SVI, positive surgical margins, or lymph node involvement. Keywords: radical prostatectomy, prostate cancer, surgical wait time, surgical delay, pathologic outcomes, prostate biopsy

Published
2019

143. Antibody-Mediated Rejection Criteria – an Addition to the Banff ′97 Classification of Renal Allograft Rejection

Author

Racusen, Lorraine C., Colvin, Robert B., Solez, Kim, Mihatsch, Michael J., Halloran, Philip F., Campbell, Patricia M., Cecka, Michael J., Cosyns, Jean-Pierre, Demetris, Anthony J., Fishbein, Michael C., Fogo, Agnes, Furness, Peter, Gibson, Ian W., Glotz, Denis, Hayry, Pekka, Hunsickern, Lawrence, Kashgarian, Michael, Kerman, Ronald, Magil, Alex J., Montgomery, Robert, Morozumi, Kunio, Nickeleit, Volker, Randhawa, Parmjeet, Regele, Heinz, Seron, Daniel, Seshan, Surya, Sund, Stale, and Trpkov, Kiril

Published
2003

145. The Banff 97 working classification of renal allograft pathology

Author

Racusen, Lorraine C., Solez, Kim, Colvin, Robert B., Bonsib, Stephen M., Castro, Maria C., Cavallo, Tito, Croker, Byron P., Demetris, A. Jake, Drachenberg, Cynthia B., Fogo, Agnes B., Furness, Peter, Gaber, Lillian W., Gibson, Ian W., Glotz, Dennis, Goldberg, Julio C., Grande, Joseph, Halloran, Philip F., Hansen, H. E., Hartley, Barry, Hayry, Pekka J., Hill, Claire M., Hoffman, Ernesto O., Hunsicker, Lawrence G., Lindblad, Anne S., Marcussen, Niels, Mihatsch, Michael J., Nadasdy, Tibor, Nickerson, Peter, Olsen, T. Steen, Papadimitriou, John C., Randhawa, Parmjeet S., Rayner, David C., Roberts, Ian, Rose, Stephen, Rush, David, Salinas-Madrigal, Luis, Salomon, Daniel R., Sund, Stale, Taskinen, Eero, Trpkov, Kiril, and Yamaguchi, Yutaka

Published
1999

146. Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate

Author

Gandhi, Jatin S., primary, Smith, Steven C., additional, Paner, Gladell P., additional, McKenney, Jesse K., additional, Sekhri, Radhika, additional, Osunkoya, Adeboye O., additional, Baras, Alexander S., additional, DeMarzo, Angelo M., additional, Cheville, John C., additional, Jimenez, Rafael E., additional, Trpkov, Kiril, additional, Colecchia, Maurizio, additional, Ro, Jae Y., additional, Montironi, Rodolfo, additional, Menon, Santosh, additional, Hes, Ondrej, additional, Williamson, Sean R., additional, Hirsch, Michelle S., additional, Netto, George J., additional, Fine, Samson W., additional, Sirohi, Deepika, additional, Kaushal, Seema, additional, Sangoi, Ankur, additional, Robinson, Brian D., additional, Kweldam, Charlotte F., additional, Humphrey, Peter A., additional, Hansel, Donna E., additional, Schultz, Luciana, additional, Magi-Galluzzi, Cristina, additional, Przybycin, Christopher G., additional, Shah, Rajal B., additional, Mehra, Rohit, additional, Kunju, Lakshmi P., additional, Aron, Manju, additional, Kryvenko, Oleksandr N., additional, Kench, James G., additional, Kuroda, Naoto, additional, Tavora, Fabio, additional, van der Kwast, Theodorus, additional, Grignon, David J., additional, Epstein, Jonathan I., additional, Reuter, Victor E., additional, and Amin, Mahul B., additional

Published
2019
Full Text
View/download PDF

147. “Renal Cell Carcinoma With Leiomyomatous Stroma” Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity

Author

Shah, Rajal B., primary, Stohr, Bradley A., additional, Tu, Zheng Jin, additional, Gao, Yuan, additional, Przybycin, Christopher G., additional, Nguyen, Jane, additional, Cox, Roni M., additional, Rashid-Kolvear, Fariborz, additional, Weindel, Michael D., additional, Farkas, Daniel H., additional, Trpkov, Kiril, additional, and McKenney, Jesse K., additional

Published
2019
Full Text
View/download PDF

150. High‐grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex

Author

Trpkov, Kiril, primary, Bonert, Michael, additional, Gao, Yuan, additional, Kapoor, Anil, additional, He, Huiying, additional, Yilmaz, Asli, additional, Gill, Anthony J, additional, Williamson, Sean R, additional, Comperat, Eva, additional, Tretiakova, Maria, additional, Magi‐Galluzzi, Cristina, additional, Brimo, Fadi, additional, and Hes, Ondrej, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results